Rasathanthra Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 18-05-2024
- Paid Up Capital ₹ 0.35 M
as on 18-05-2024
- Company Age 41 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 6.00 M
as on 18-05-2024
- Revenue -2.68%
(FY 2017)
- Profit 6.88%
(FY 2017)
- Ebitda 5.27%
(FY 2017)
- Net Worth 6.06%
(FY 2017)
- Total Assets 16.39%
(FY 2017)
About Rasathanthra Pharmaceuticals
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.35 M.
The company currently has active open charges totaling ₹6.00 M.
Eranchithodi Basim, Venmenad Aneesh, Madhusoodanan Arjun, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24231KL1983PTC003748
- Company No.
003748
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Jul 1983
- Date of AGM
10 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Ernakulam
Industry
Company Details
- Location
Palakkad, Kerala, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Rasathanthra Pharmaceuticals?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajnarayan Narayanan  | Managing Director | 13-May-2007 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Eranchithodi Basim | Additional Director | 16-Dec-2022 | Current |
| Venmenad Aneesh | Director | 19-Nov-2021 | Current |
| Madhusoodanan Arjun | Director | 19-Nov-2021 | Current |
| Murinjara Chandrasekharan | Director | 28-Aug-2008 | Current |
Financial Performance of Rasathanthra Pharmaceuticals.
Rasathanthra Pharmaceuticals Pvt Ltd, for the financial year ended 2017, experienced Minor drop in revenue, with a 2.68% decrease. The company also saw a slight improvement in profitability, with a 6.88% increase in profit. The company's net worth moved up by a moderate rise of 6.06%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Rasathanthra Pharmaceuticals?
In 2017, Rasathanthra Pharmaceuticals had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ayur Siddha Pharmaceuticals Private LimitedActive 5 years 1 monthMurinjara Chandrasekharan is a mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Mar 2019 | ₹6.00 M | Open |
How Many Employees Work at Rasathanthra Pharmaceuticals?
Rasathanthra Pharmaceuticals has a workforce of 7 employees as of Apr 02, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Rasathanthra Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Rasathanthra Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
